Department of Health and Human Services February 26, 2007 – Federal Register Recent Federal Regulation Documents

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent 6,756,038 and PCT Application Serial No. PCT/US98/19794 and foreign equivalents thereof, entitled ``Agonist and Antagonist Peptides of Carcinoembryonic Antigen (CEA)'' (E-099-1996/0) and U.S. Patent 6,969,582 and PCT Application Serial No. PCT/US99/26866 and foreign equivalents thereof, entitled ``A Recombinant Vector Expressing Multiple Costimulatory Molecules and Uses Thereof'' (E-256-1998/0), to GlobeImmune Inc., which is located in Louisville, Colorado. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use recombinant Saccharomyces cerevisiae expressing CEA for the prevention and treatment of cancer.

CERHR announces availability of the hydroxyurea expert panel report by March 5, 2007 on the CERHR Web site (https:// cerhr.niehs.nih.gov) or in print from CERHR (see ``ADDRESSES'' below). This expert panel report is an evaluation of the reproductive and developmental toxicity of hydroxyurea conducted by a 13-member expert panel composed of scientists from the Federal Government, universities, and private organizations. CERHR invites the submission of public comments on this expert panel report.